Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males ≥ 18 years of age~2. Pathologically confirmed, adenocarcinoma of the prostate with either high-tier intermediate or high risk prostate cancer:~   a. High-tier intermediate risk prostate cancer: i. Gleason score = 7 and PSA 10 - 20 ng/mL b. High risk prostate cancer: i. any T3; or ii. Gleason Score ≥ 8.0; or iii. PSA ≥ 20 ng/mL.~3. Normoglycemic or Impaired Fasting Glucose45 defined as:~   1. Fasting Plasma Glucose of ≤ 6.9; or~  2. HbA1c of \<6.5%~4. Deemed fit to undergo curative intent external beam radiation therapy with concurrent androgen deprivation therapy by their attending radiation oncologist.~5. Accessible for follow-up clinical and laboratory assessments.~Exclusion Criteria:~1. Patients with evidence (either by imaging or pathology) of distant metastatic spread of their disease.~   a. Patients with pelvic lymph nodes (i.e. N1 disease) are NOT considered to have distant metastases and can be included in the trial, if meeting the other study criteria.~2. Patients that meet ≥1 of the Canadian Diabetes Association criteria45 for the diagnosis of diabetes:~   1. Fasting Plasma Glucose of ≥ 7.0 mmol/L; or~  2. HbA1C ≥ 6.5%; or~  3. Plasma Glucose level of ≥ 11.1 mmol/L 2 hours following a 75g oral glucose load, if known, within past 28 days; or~  4. Random Plasma Glucose level of ≥ 11.1 mmol/L, if known, within past 28 days~3. Patient who currently take metformin or those who have taken metformin within the past 12 months.~4. History of lactic acidosis or conditions that predispose to lactic acidosis including32:~   a. Impaired Renal Function (eGFR \< 30); or b. Liver disease, including alcoholic liver disease, as demonstrated by any of the following parameters: i. AST \>1.8 x the upper limit of normal ii. ALT \> 1.8 x the upper limit of normal iii. Alkaline Phosphatase \> 2x the upper limit of normal iv. Serum total bilirubin ≥ upper limit of normal c. Alcohol abuse (habitual intake of ≥3 alcoholic beverages per day) sufficient to cause hepatic toxicity d. Severe infection~5. Patients with prior bilateral orchiectomy.~6. Patients with prior prostatectomy~7. Patients who are unable to provide informed consent~8. Prior history of malignancy (with exception of adequately treated non-melanomatous skin cancer or other solid tumors treated curatively with no evidence of disease for ≥ 5 years).~9. Patients on hormonal therapy for more than 3 months prior to registration in the trial.~   -

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: EXPERIMENTAL): Metformin 500 mg PO TID x 30-36 months
- Placebo (Type: PLACEBO_COMPARATOR): Identical placebo TID x 30-36 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy